The Framingham pharmaceutical firm Alzheon has partnered with the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences to develop a diagnostic assay to measure substances believed to be neurotoxic drivers of Alzheimer’s disease pathology.